期刊文献+

高效液相色谱-质谱法测定盐酸厄洛替尼中潜在致突变杂质0419

A Convenient and User-friendly LC-MS/MS Analysis Method was Established for the Determination of Genotoxic Impuritiesin Erlotinib Hydrochloride
在线阅读 下载PDF
导出
摘要 目的:建立盐酸厄洛替尼中潜在致突变杂质0419的测定方法。方法:采用高效液相色谱-质谱法,用十八烷基硅烷键合硅胶为填充剂(Agilent Poroshell 120 EC-C 18,4.6 mm×50 mm,2.7μm);以0.05%甲酸水溶液为流动相A,乙腈溶液为流动相B;柱温30℃;样品控温10℃;流速0.4 mL/min,进样体积10μL。结果:致突变杂质0419在0.61~121.58 ng/mL线性范围良好,定量限为0.61 ng/mL,检测限为0.12 ng/mL,回收率为92.6%,溶液稳定性良好。结论:该方法可以准确检测盐酸厄洛替尼中杂质0419的含量。 Objective:A convenient and user-friendly LC-MS/MS analysis method was established for the determination of genotoxic impurities in erlotinib hydrochloride.Method:The following HPLC conditions are follows:separated on a C 18(Agilent Poroshell 120 EC-C 18,4.6 mm×50 mm,2.7μm)column maintained at 30℃,mobile phase A was 0.05 mol/L formic acid water solution,mobile phase B was ACN,gradient elution was used.The flow-rate was 0.4 mL/min and 10μL.Result:The assay was linear over the range 0.61~121.58 ng/mL with a limit of quantitiation of 0.61 ng/mL with a limit of detection of 0.12 ng/mL.The recovery rate of impurity was 92.6%and stabilities were good.Conclusion:The method can accurately determine the content of impurity 0419 in erlotinib hydrochloride.
作者 孙琳 周君安 曹秀芝 魏娜 Sun Lin;Zhou Jun′an;Cao Xiuzhi;Wei Na(Jiangsu Hansoh Pharmaceutical Co.,Ltd.,Lianyungang 222000,China)
出处 《山东化工》 CAS 2023年第1期138-139,146,共3页 Shandong Chemical Industry
关键词 盐酸厄洛替尼 高效液相色谱-质谱法 潜在致突变杂质 erlotinib hydrochloride LC-MS/MS genotoxic impurities
作者简介 孙琳,女,中级工程师,主要从事新药的质量研究及申报工作。
  • 相关文献

参考文献5

二级参考文献52

  • 1刘敏,胡昌勤.力达霉素标准品量值传递方法的研究[J].药物分析杂志,2004,24(4):380-384. 被引量:14
  • 2American Cancer Society.Cancer Facts and Figures 2008[EB/OL].2009-07-13[2010-06-25].http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf.
  • 3World Health Organization.Fact Sheet No.310[EB/OL].2009-07-13[2010-06-25].http://www.who.int/mediacentre/factsheets/fs310/en/index.html.
  • 4Postmus P E,Smit E F.Chemotherapy for brain metastases of lung cancer:a Review[J].Ann Oncol,1999,10(7):753-759.
  • 5Endelsohn J,Baselga J.Status of the epidermal growth factor receptor antagonists in the biology and treatment of cancer[J].J Clin Oncol,2003,21(14):2787-2799.
  • 6Herbst R S,Shin D M.Monoclonal antibodies to target epidermal growth factor receptor-positive tumors:a new paradigm for cancer therapy[J].Cancer,2002,94(5):1593-1611.
  • 7Metro G,Finocchiaro G,Cappuzzo F.Anti-cancer therapy with EGFR inhibitors:factors of prognostic and predictive significance[J].Ann Oncol,2006,17(suppl 2):842-845.
  • 8Mok T,Wu Y-L,Thongprasert S,et al.Phase Ⅲ,randomized,open-label,first-line study of gefitinib(G)versus carboplatin/paclitaxel(C/P)in clinically selected patients(pts)with advanced non-small-cell lung cancer(NSCLC)[J].Ann Oncol,2008,19(suppl8):1-4.
  • 9Hirsch F R,Varella-Garcia M,Bunn PA Jr,et al.Epidermal growth factor receptor in non-small-cell lung carcinomas:correlation between gene copy number and protein expression and impact on prognosis[J].J Clin Oncol,2003,21:3798-3807.
  • 10Hirsch F R,Varella-Garcia M,Bunn P A Jr,et al.Molecular predictors of outcome with gefitinib in a phase Ⅲ placebo-controlled study in advanced nonsmall-cell lung cancer[J].J Clin Oncol,2006,24:5034-5042.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部